Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24) Meeting Abstract
| Authors: | Jacobson, C. A.; Chavez, J. C.; Sehgal, A.; William, B. M.; Munoz, J.; Salles, G. A.; Casulo, C.; Munshi, P. N.; Maloney, D. G.; De Vos, S.; Reshef, R.; Leslie, L. A.; Yakoub-Agha, I.; Oluwole, O. O.; Fung, H. C. H.; Plaks, V.; Yang, Y.; Lee, J.; Avanzi, M. P.; Neelapu, S. S. |
| Abstract Title: | Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604112 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.7515 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7515 -- Source: Wos |
